BriaCell Therapeutics Corp.

BCTXWNASDAQHealthcare

$0.00

$-0.00(-0.00%)

Market Cap$1695

P/E Ratio—

52W High$0.0645

52W Low$0.0006

Avg Volume71K

Open$0.00

Beta2.03

Overview

BriaCell Therapeutics Corp. (BCTXW) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

BCTXW · earnings · updated Jun 9, 2026

Latest Earnings

Q4 FY2023Report Date: Oct 31, 2023

EPS Actual

$0.36

Revenue

—

Fiscal Period

Q4 FY2023

FY ends December

Report Date

Oct 31, 2023

After Market Close

BCTXW reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

—

Days Away84

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.—

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
— Q4 FY2023	Oct 31, 2023	—	$0.36	—	—	—	—
— Q2 FY2023	Apr 30, 2023	—	-$315.47	—	—	—	—
— Q1 FY2023	Jan 31, 2023	—	-$765.68	—	—	—	—
— Q4 FY2022	Oct 31, 2022	—	-$315.47	—	—	—	—
— Q3 FY2022	Jul 31, 2022	—	-$1242.25	—	—	—	—
— Q4 FY2021	Oct 31, 2021	—	$58.47	—	—	—	—
— Q3 FY2021	Jul 31, 2021	—	$147.85	—	—	—	—

Q4 FY2023

Oct 31, 2023

EPS Actual

$0.36

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2023

Apr 30, 2023

EPS Actual

-$315.47

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2023

Jan 31, 2023

EPS Actual

-$765.68

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2022

Oct 31, 2022

EPS Actual

-$315.47

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2022

Jul 31, 2022

EPS Actual

-$1242.25

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2021

Oct 31, 2021

EPS Actual

$58.47

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2021

Jul 31, 2021

EPS Actual

$147.85

EPS Est.

—

EPS Surpr.

—

Revenue

—

Analyst Estimates

EPS Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2025	$0.00	$0.00	$0.00	0

Revenue Estimates

Period	Low	Consensus	High	# Analysts
Q4 FY2025	$0.0B	$0.0B	$0.0B	1

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
— Q4 FY2023	Oct 31, 2023	—	$1.00	$1.13	+13.00%
— Q2 FY2023	Apr 30, 2023	—	$3.02	$2.99	-0.99%
— Q1 FY2023	Jan 31, 2023	—	$3.05	$2.99	-1.97%
— Q4 FY2022	Oct 31, 2022	—	$2.26	$2.77	+22.57%
— Q3 FY2022	Jul 31, 2022	—	$2.85	$2.88	+1.05%
— Q4 FY2021	Oct 31, 2021	—	$4.65	$4.59	-1.29%
— Q3 FY2021	Jul 31, 2021	—	$1.76	$1.85	+5.11%

Q4 FY2023+13.00%

Report Date

Oct 31, 2023

EPS Beat/Miss

—

Price Before

$1.00

Price After

$1.13

Q2 FY2023-0.99%

Report Date

Apr 30, 2023

EPS Beat/Miss

—

Price Before

$3.02

Price After

$2.99

Q1 FY2023-1.97%

Report Date

Jan 31, 2023

EPS Beat/Miss

—

Price Before

$3.05

Price After

$2.99

Q4 FY2022+22.57%

Report Date

Oct 31, 2022

EPS Beat/Miss

—

Price Before

$2.26

Price After

$2.77

Q3 FY2022+1.05%

Report Date

Jul 31, 2022

EPS Beat/Miss

—

Price Before

$2.85

Price After

$2.88

Q4 FY2021-1.29%

Report Date

Oct 31, 2021

EPS Beat/Miss

—

Price Before

$4.65

Price After

$4.59

Q3 FY2021+5.11%

Report Date

Jul 31, 2021

EPS Beat/Miss

—

Price Before

$1.76

Price After

$1.85

Beat Rate0 / 7 quarters

Largest Move+22.57% (Q4 FY2022)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

BriaCell Therapeutics Corp. (BCTXW) most recently reported earnings on October 31, 2023 for Q4 FY2023, posting EPS of $0.36 (in line with the analyst consensus of —). The next BCTXW earnings date is expected around September 1, 2026.

Each quarter, investors track BCTXW earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BCTXW revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

BCTXW's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

BCTXW earnings · 4 questions

BriaCell Therapeutics Corp.'s next earnings report is expected around September 1, 2026. BCTXW typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BCTXW historically reports after market close (AMC).

BCTXW earnings datewhen is BCTXW earningsBCTXW next earnings datewhen does BCTXW report earningsBCTXW earnings calendar

▸ Source: FMP · BriaCell Therapeutics Corp. SEC filings · US GAAP · BriaCell Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026